Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Liabilities (2019 - 2026)

Summit Therapeutics filings provide 8 years of Other Non-Current Liabilities readings, the most recent being $1.8 million for Q1 2026.

  • Quarterly Other Non-Current Liabilities rose 5.33% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Mar 2026, up 5.33% year-over-year, with the annual reading at $1.8 million for FY2025, 12.39% up from the prior year.
  • Other Non-Current Liabilities hit $1.8 million in Q1 2026 for Summit Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $3.3 million in Q1 2024 and bottomed at $1.4 million in Q4 2022.
  • Average Other Non-Current Liabilities over 5 years is $1.9 million, with a median of $1.7 million recorded in 2024.
  • The largest annual shift saw Other Non-Current Liabilities crashed 48.52% in 2022 before it skyrocketed 123.5% in 2024.
  • Summit Therapeutics' Other Non-Current Liabilities stood at $1.4 million in 2022, then rose by 9.31% to $1.6 million in 2023, then grew by 4.35% to $1.6 million in 2024, then grew by 12.39% to $1.8 million in 2025, then fell by 1.8% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Other Non-Current Liabilities are $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $1.8 million (Q3 2025).